Time Pas­sages: Bruce Gold­smith out at Jim Wilson's gene ther­a­py biotech; Flag­ship re­veals Michael Sev­eri­no’s CEO gig

→ When Pas­sage Bio read­just­ed its pipeline pri­or­i­ties, pruned its work­force by 13% and saw its R&D chief Eliseo Sali­nas walk out in March, it would be nat­ur­al to as­sume that this con­flu­ence of events could lead to more im­mi­nent changes. This week, CEO Bruce Gold­smith fol­lowed Sali­nas and board mem­ber Liam Rat­cliffe out the door.

Pas­sage Bio and Gold­smith both felt it was in their best in­ter­ests to move on as the Jim Wil­son biotech shifts its fo­cus to GM1 gan­gliosi­do­sis, Krabbe dis­ease and fron­totem­po­ral de­men­tia. Gen­er­al coun­sel and cor­po­rate sec­re­tary Edgar “Chip” Cale has been named in­ter­im chief as the search gets un­der­way for Gold­smith’s re­place­ment, hav­ing leaped to Pas­sage Bio in 2019 af­ter a 21-year ca­reer at GSK that con­clud­ed as SVP, le­gal cor­po­rate projects. Gold­smith left Deer­field to suc­ceed co-founder Stephen Squin­to as Pas­sage Bio’s CEO in ear­ly 2020.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA